+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
New

Cancer Diagnostics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 189 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011653
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer diagnostics market is undergoing significant transformation as technology and clinical innovation reshape approaches to oncology care. Senior executives are meeting increasing complexity, making strategic decisions around investment, operations, and technology to remain competitive and resilient as this sector grows.

Market Snapshot: Cancer Diagnostics Market Overview

The Cancer Diagnostics Market expanded from USD 37.02 billion in 2025 to USD 41.15 billion in 2026 with a projected CAGR of 12.26%. Market value is set to reach USD 83.23 billion by 2032. This growth reflects the rapid integration of molecular data, advanced imaging modalities, and single-cell analytics, which are profoundly influencing clinical workflows and supporting the adoption of new diagnostic technologies on a global scale. As stakeholders navigate these advances, the need for coordinated and strategic deployment continues to drive technology investment, regional development, and expansion of clinical capabilities across end-user groups.

Cancer Diagnostics Market Scope & Segmentation

  • Technology Types: Flow cytometry, advanced imaging modalities (such as CT, MRI, PET, ultrasound), immunohistochemistry (chromogenic and fluorescent), in situ hybridization, microarray platforms, PCR methods, and high-throughput sequencing technologies are key components advancing precision and efficiency in diagnostics. Each technology presents unique advantages, from sensitivity to scalability, and caters to evolving laboratory and clinical needs.
  • Cancer Types: Hematological cancers—including leukemia, lymphoma, and multiple myeloma—benefit from single-cell and cytogenetic techniques, while solid tumors like breast, lung, colorectal, and prostate cancers increasingly require integrated imaging and molecular diagnostics. This shift supports enhanced stratification and enables more personalized treatment protocols for complex disease presentations.
  • End-User Categories: Hospitals, diagnostic laboratories, ambulatory care centers, and research institutions each pursue cancer diagnostic technologies aligned with their unique workflow requirements. Hospitals and ambulatory settings demand user-friendly, integrated solutions, while laboratories prioritize throughput and standardization. Research institutions seek platforms with flexibility to accommodate novel investigative approaches.
  • Regions: Market analysis spans major geographies, including the Americas—characterized by growth in integrated health networks and expansion of precision oncology initiatives. Europe, the Middle East, and Africa focus on regulatory compliance, varying rates of adoption, and centralized testing trends. Asia-Pacific stands out for rapid adoption of digital pathology and sequencing, driven by public-private collaboration and expanding infrastructure.

Key Takeaways for Oncology Diagnostics Stakeholders

  • Clinical decision-making improves through the integration of imaging, molecular diagnostics, and immunoassays, leading to adaptive treatment strategies in precision oncology workflows.
  • Laboratories and care providers are benefiting from rapid, multiplexed assays, which increase diagnostic throughput and support timely interventions, enhancing care delivery within critical clinical windows.
  • Adoption trends and solution preferences vary significantly by region, driven by infrastructure investments, interoperability, local manufacturing, and efforts toward harmonized regulatory environments.
  • Stakeholder preferences reflect demand for turnkey solutions within hospitals and ambulatory settings, standardized high-throughput capabilities within laboratories, and configurable technology platforms for academic and private research organizations.
  • Collaboration between manufacturers, laboratories, and research bodies remains central to accelerating co-development, validation, and clinical translation of next-generation diagnostic innovations.

Tariff Impact: Navigating United States Trade Policy Changes

New United States tariffs introduced in 2025 have injected added complexity into cancer diagnostics supply chains. Adjustments in import costs for equipment and reagents compel procurement leaders to prioritize resilient sourcing, diversify suppliers, and consider regional hub strategies to mitigate risk. Manufacturers are reevaluating localization and distribution, while health systems are increasing inventory buffers and seeking alternative arrangements to maintain uninterrupted diagnostic services. Organizations prepared with global sourcing strength or exclusive local partnerships are positioned to adapt more effectively and maintain continuity in supply and service delivery.

Methodology & Data Sources

This market research integrates primary clinician and procurement expert interviews with thorough validation from peer-reviewed literature, regulatory frameworks, and technical reports. Techniques such as technology mapping, structured segmentation, and scenario analysis ensure that insights are actionable, reproducible, and grounded in both real-world and validated evidence.

Why This Report Matters

  • Enables leaders to align technology strategy, procurement practices, and data-driven programs with shifting oncology models and emerging patient care demands.
  • Delivers actionable segmentation and regional analysis to support capital planning decisions, optimize supplier relationships, and inform strategic partnership development in cancer diagnostics.
  • Facilitates effective risk management for tariff changes, regulatory shifts, and operational disruptions, reinforcing supply chain resilience and preparedness across market cycles.

Conclusion

In a rapidly developing field, the intersection of technology, operational efficiency, and regulatory adaptation positions organizations to advance precision oncology and maintain a sustainable competitive edge in the cancer diagnostics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cancer Diagnostics Market, by Technology
8.1. Flow Cytometry
8.1.1. Cell Sorting
8.1.2. Multiparameter Flow Cytometry
8.2. Imaging
8.2.1. Computed Tomography
8.2.2. Magnetic Resonance Imaging
8.2.3. Positron Emission Tomography
8.2.4. Ultrasound
8.3. Immunohistochemistry
8.3.1. Chromogenic
8.3.2. Fluorescent
8.4. In Situ Hybridization
8.5. Molecular Diagnostics
8.5.1. Microarray
8.5.2. Pcr
8.5.3. Sequencing
9. Cancer Diagnostics Market, by Cancer Type
9.1. Hematological Cancers
9.1.1. Leukemia
9.1.2. Lymphoma
9.1.3. Multiple Myeloma
9.2. Solid Tumors
9.2.1. Breast Cancer
9.2.2. Colorectal Cancer
9.2.3. Lung Cancer
9.2.4. Prostate Cancer
10. Cancer Diagnostics Market, by End User
10.1. Ambulatory Care
10.2. Diagnostic Laboratories
10.3. Hospitals
10.4. Research Institutes
10.4.1. Academic Institutes
10.4.2. Private Research Centers
11. Cancer Diagnostics Market, by Region
11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific
12. Cancer Diagnostics Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Cancer Diagnostics Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. United States Cancer Diagnostics Market
15. China Cancer Diagnostics Market
16. Competitive Landscape
16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. Abbott Laboratories
16.6. Agilent Technologies, Inc.
16.7. Becton, Dickinson and Company
16.8. Bio-Rad Laboratories, Inc.
16.9. bioMérieux SA
16.10. Canon Medical Systems Corporation
16.11. Danaher Corporation
16.12. Danaher Corporation
16.13. DiaSorin S.p.A.
16.14. F. Hoffmann-La Roche Ltd
16.15. Fujifilm Corporation
16.16. GE HealthCare Technologies Inc.
16.17. Hologic, Inc.
16.18. Illumina, Inc.
16.19. Myriad Genetics, Inc.
16.20. NeoGenomics Laboratories, Inc.
16.21. PerkinElmer, Inc.
16.22. QIAGEN N.V.
16.23. Quest Diagnostics Incorporated
16.24. Siemens Healthineers AG
16.25. Sysmex Corporation
16.26. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 150. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 152. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 153. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 154. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 155. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 156. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 157. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 159. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 172. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 174. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 175. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 176. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 177. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 178. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 179. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 180. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 181. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 197. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 198. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 199. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 200. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 201. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 202. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 203. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 204. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 206. GCC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. GCC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 208. GCC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 209. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 210. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 211. GCC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 212. GCC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 213. GCC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 214. GCC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 215. GCC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. GCC CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 228. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 230. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 231. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 232. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 233. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 234. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 235. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 236. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 237. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 239. G7 CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 240. G7 CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 241. G7 CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 242. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 243. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 244. G7 CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 245. G7 CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 246. G7 CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 247. G7 CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 248. G7 CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 249. G7 CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 250. NATO CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 251. NATO CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 252. NATO CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 253. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 254. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 255. NATO CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 256. NATO CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 257. NATO CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 258. NATO CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 259. NATO CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. NATO CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 261. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 273. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 274. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 275. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 276. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 277. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 278. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 279. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 280. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 281. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 282. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 283. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Cancer Diagnostics market report include:
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • Danaher Corporation
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 41.15 Billion
Forecasted Market Value ( USD ) by 2032 $ 83.23 Billion
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Canine Cancer Screening Market - Global Forecast 2026-2032 - Product Image

Canine Cancer Screening Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Head & Neck Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Head & Neck Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities - Product Image

Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities

  • Report
  • 278 Pages
  • Global
From
Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2025-2033 - Product Image

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2025-2033

  • Report
  • 145 Pages
  • Global
From
Advanced Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test (Tumor Marker Tests, Fine Needle Aspiration Cytology (FNAC) & Biopsy, Imaging-Based Diagnostics, Bone Marrow Aspiration & Biopsy), End-use, and Region with Growth Forecasts, 2025-2033 - Product Image

Advanced Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test (Tumor Marker Tests, Fine Needle Aspiration Cytology (FNAC) & Biopsy, Imaging-Based Diagnostics, Bone Marrow Aspiration & Biopsy), End-use, and Region with Growth Forecasts, 2025-2033

  • Report
  • 130 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.